Up almost 8% in after hours....!
When the shorts thought that the Ebola vaccine would rip them a new one...
Then comes along news that Novavax's H7N9 will be granted fast-tracked status....
The New England Journal of Medicine published Phase 1 clinical trial results for this H7N9 vaccine .
This is the same vaccine Novavax created in 90 days....!!!!!!
And the blockbusting RSV vaccine is going into Phase 2 clinical trials too...!
LOL, gotta love it...!
Talk about a knock-out for shorts.....
What is interesting is that Novavax is now dancing with the $5.40ish area.
That is exactly were the price "hovered around" on Monday before the CNBC exposure.
Also, that is right at one of my old trend lines that I have, starting from mid-July.
Maybe coincidence, but this $5.40ish appears to be developing as a support/resistance area.
Rez, anyone doing their DD like you've done will find the same results:
Novavax is a monumental investment opportunity for the long run...
and that "long run" is now just one or two years out, IMHO.
Novavax is absolute positives, an absolute gem...
Great to have official news that Novavax is developing a promising Ebola vaccine...!
Yet, very little publicity since that initial announcement on Monday.
No follow-up from institutions, analysts, Seeking Alpha, Market Watch, etc.....
and nothing from major business outlets since that excellent CNBC interview.
Some trickling of information through regular news outlets....
This quiet approach may in part be why the price has been so weak...?
This retracement from Monday's 13% rise is frustrating, but hang-in there....
The level of retracement surprises me too, but....
We'll see the price get back to the upswing as more investors recognize Novavax
The word about Novavax will continue to spread, helping the price upward.
Here is an article from the Washington Post, so there is some news trickling out.
Today's retracement is A LOT more than I thought would happen.
So, kudos to Robert for his call...
This Ebola vaccine news WILL create a whole new dynamic of support and resistance levels.
I'd think today's closing price will be the start of a new support level.
Right now, I'm just using some old trend lines.....
One is right where the price is settling right now...
We'll see if it holds...
Look at yesterday's trading.
There was very quiet trading until CNBC announced Novavax.
Then, the explosion of the volume and price happened.
NO follow-up news today, so far....
When will the next round of news hit to bring back the attention to Novavax?
What will be the next round of news?
Institutional coverage, another interview with Stan Erck, a major article about Novavax....?
The ride higher is far from over...
There is absolutely NO follow-up news or articles today.
Nothing to drive the price higher, but allows herding the retails to sell shares.
Institutions will triumph over those with weak holdings of Novavax
Yes, the price will be much higher... today is clean-up
The upward trend is underway, will still have plenty of volatility....
The unwinding of weak hands is mostly done for now....
The $5.68 to $5.75 will be resistance area and tough to breach
Another CNBC-like moment will make that happen.
Looks like $5.60 is the support level, so far.
If anyone wants to nibble on some shares, this may be the time to make that buy...
Double digits within weeks.
Novavax's RSV vaccine will be a major player in the $5bln RSV market.
Novavax's H7N9's stunning Phase 1 clinical trial was published in the New England Journal of Medicine.
What happens when H7N9 ramps up this year?
Now, Novavax is making waves with their Ebola vaccine.
Your price target of $50 to $100 by 2017 is very reasonable...
Rez and all, my responses to posts are often written for the general audience. Rez, you already know what I'm stating, so my post is not discounting what you already know... my response is for newbies so THEY get to know Novavax's future.
These small share pre-market trades is contrived, IMHO.
Short positions still need to escape before the price reaches double digits.
Little buying this morning since Novavax is still relatively "under the radar".
This allows the shenanigans we are seeing pre-market.
Expect another round of explosive buying if Stan Erck goes onto FBN today.
We close above $6.00 today
Any consolidation will be short lived...
expecting more publicity today
Short positions still need to unwind, have to buy-back shares.
The price will close today well into the $6 range.
Companies becoming an "Ebola play" have experienced a 3 fold increase
Novavax WILL be double-digits within weeks....
Novavax WILL be understood as a serious contender, if not the absolute best.
Novavax's RSV vaccine is considered to be " disruptive " to the vaccine industry.
Novavax's CEO, Stan Erck would push their Ebola ONLY if it is VERY promising.
Erck would not risk damaging Novavax's reputation with an unworthy Ebola vaccine.
Novavax is ALREADY developing a blockbuster vaccine with their RSV vaccine.
logistics will be a major plus!
Stan would only raise awareness of the Ebola vaccine ONLY if the it looked incredibly promising.
He'd NEVER risk the company's reputation on an Ebola vaccine when the blockbuster RSV vaccine is a cornerstone to Novavax's future.
We investors should be very comfortable that Novavax is going to be a household name very soon.